The Onyx drugs would add to Amgen's pipeline of new drugs. In the first half of 2014 Amgen expects to announce late-stage testing data for three experimental drugs. The products are being studied as treatments for skin cancer, recurrent ovarian cancer and high LDL, or bad cholesterol, that doesn't respond to pills, like Lipitor.

Onyx and Pfizer Inc. are also studying a drug called palbociclib as a treatment for breast cancer, and oprozomib, a potential multiple myeloma drug that is in early clinical testing.
Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback